drugset / Trial / NCT02733432
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if two topical formulations of CD101 are safe and effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC) compared to oral fluconazole.
Timeline
- Start
- 2016-06-08
- Primary completion
- 2016-11-23
- Completion
- 2016-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluconazole | Small molecule | 150 mg | Oral |
| Subject | Rezafungin | Other / unclassified | 1 % | Topical |
| Subject | Rezafungin | Other / unclassified | 3 % | Topical |
| Subject | Rezafungin | Other / unclassified | 6 % | Topical |